Lantheus completes Progenics purchase

By staff writers

June 22, 2020 -- Lantheus Holdings, parent company of Lantheus Medical Imaging, has completed its purchase of oncology drug developer Progenics Pharmaceuticals.

The deal was first announced in October of last year. Under the purchase terms, Progenics stockholders have received 0.31 share of Lantheus stock for each share of Progenics stock. They also received nontradeable contingent value right that is payable on completion of milestones related to the financial performance of PyLTM, Progenics' prostate-specific imaging agent.

Progenics will be delisted from Nasdaq, Lantheus said.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking